Skip to main content

Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 31 March 2021

Shanghai Cathay Biotech
CHF
292
million
Harmony Biosciences
CHF
145
million
CHF
82
million
bioatla
ALX Oncology
CHF
65
million
CHF
59
million
Swixx BioPharma
CHF
56
million
Y-mAbs Therapeutics
CHF
53
million
Neurelis